Chronic Hepatitis B
Conditions
Interventions
Multiple Drug-Resistant Chronic Hepatitis B with NUCs Combination treatment group:TAF
Sponsors
Third Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Chronic HBV infected patients confirmed by liver biochemistry, serology, transient liver elastography, and/or liver pathology Male or female adult (age >18 years) Compensated liver function Treated with NUCs combination( ETV+ADV; ETV+TDF; LDT+ADV; LDT+TDF; LAM+ADV; LAM+TDF) HBV resistant HBV DNA < 69IU/ml ALT< 10 ULN Patient is able to give written informed consent prior to study start and to comply Medication compliance ranges from 80% to 120%.
Exclusion criteria
Exclusion criteria: Evidence of decompensated liver disease Evidence of primary hepatic carcinoma Coinfected with HCV or HIV Evidence of other autoimmune or metabolic liver diseases (except non-alcoholic fatty liver disease) Other malignant tumor(except those cured) Current abuse of illegal drugs or alcohol, sufficient in the investigator's opinion to prevent adequate compliance with study therapy or to increase the risk of hepatotoxicity or pancreatitis Women who are pregnant or breastfeeding Other serious medical conditions that might preclude completion of this study or that require chronic administration of prohibited medications Moribund state including advanced/pre-terminal liver cancer or other non-hepatic cancers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBV-DNA; | — |
Secondary
| Measure | Time frame |
|---|---|
| ALT;HBsAg HBsAb HBeAg HBeAb HBcAb;creatinine;Ca;P;TC?TG?HDL?LDL;GLU; | — |
Countries
China
Contacts
Public ContactNan Yuemin
the third hospital of Hebei medical university
Outcome results
None listed